NasdaqGS:AMGNBiotechs
Is It Time To Reassess Amgen (AMGN) After A Steady Share Price And Strong DCF Case
You might be wondering whether Amgen at around US$329 is offering fair value right now or if the current price is out of line with what the business looks worth.
The stock has been fairly steady year to date with a 0.4% return, although the recent 7 day and 30 day returns of 5.0% and 3.2% declines sit against a stronger 24.7% return over the past year and 52.7% to 55.6% returns across the past 3 to 5 years.
Recent headlines around Amgen have focused on its position in large cap biotech,...